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ABSTRACT
Introduction: Obstructive sleep apnoea (OSA), the
most common type of sleep-disordered breathing, is
associated with significant immediate and long-term
morbidity, including fragmented sleep and impaired
daytime functioning, as well as more severe
consequences, such as hypertension, impaired
cognitive function and reduced quality of life.
Perioperatively, OSA occurs frequently as a
consequence of pre-existing vulnerability, surgery
and drug effects. The impact of OSA on
postoperative respiratory complications (PRCs) needs
to be better characterised. As OSA is associated with
significant comorbidities, such as obesity, pulmonary
hypertension, myocardial infarction and stroke, it is
unclear whether OSA or its comorbidities are the
mechanism of PRCs. This project aims to (1)
develop a novel prediction score identifying surgical
patients at high risk of OSA, (2) evaluate the
association of OSA risk on PRCs and (3) evaluate if
pharmacological agents used during surgery modify
this association.
Methods: Retrospective cohort study using hospital-
based electronic patient data and perioperative data
on medications administered and vital signs. We will
use data from Partners Healthcare clinical databases,
Boston, Massachusetts. First, a prediction model for
OSA will be developed using OSA diagnostic codes
and polysomnography procedural codes as the
reference standard, and will be validated by medical
record review. Results of the prediction model will be
used to classify patients in the database as high,
medium or low risk of OSA, and we will investigate
the effect of OSA on risk of PRCs. Finally, we will
test whether the effect of OSA on PRCs is modified
by the use of intraoperative pharmacological agents
known to increase upper airway instability, including
neuromuscular blockade, neostigmine, opioids,
anaesthetics and sedatives.
Ethics and dissemination: The Partners Human
Research Committee approved this study (protocol
number: 2014P000218). Study results will be made
available in the form of manuscripts for publication
and presentations at national and international
meetings.
INTRODUCTION
Background
Obstructive sleep apnoea (OSA) is a common
disorder characterised by recurrent collapse
of the upper airway. This chronic condition
may be diagnosed by the presence of symp-
toms and, depending on the speciﬁc criteria
used for making the diagnosis, more than ﬁve
episodes of apnoea, hypopnoea or respiratory
effort-related arousal per hour of sleep
(apnoea hypopnoea index, AHI, ≥5/h).1 2
Daytime symptoms refer to excessive daytime
sleepiness, morning headaches, decreased
concentration, memory loss, decreased libido
and irritability. Other OSA-related symptoms
include witnessed apnoea, snoring, non-
refreshing sleep, and gasping or choking at
night.3
Recent epidemiological data report that an
estimated 70 million people in the USA
alone are affected by OSA, making it the
most common type of sleep-disordered
breathing (SDB).4 5 In the general adult
Strengths and limitations of this study
▪ This work uses a large clinical database consist-
ing of preoperative, intraoperative and post-
operative patient data.
▪ Our prediction model draws on well-established
clinical characteristics associated with obstruct-
ive sleep apnoea (OSA) as well as new measures
aimed at improving dynamic risk assessment in
a perioperative setting.
▪ The results of this study may enable periopera-
tive clinicians to identify adult surgical patients at
highest risk for OSA, optimise preoperative inter-
ventions, and appropriately triage care post-
operatively based on intraoperative events.
▪ Potential limitations relate to the need for valid-
ation studies in data sets from other institutions
to determine generalisability of prediction score.
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population, approximately 13% of men and 6% of
women have moderate-to-severe SDB, deﬁned as AHI
≥15/h.5 It is also estimated that 14% of men and 5% of
women have AHI ≥5/h plus daytime symptoms.5 The
prevalence of SDB without daytime symptoms is even
higher and reaches values of up to 9% in women and
24% in men.2 6 It is possible that such epidemiological
data underestimate the frequency of OSA among today’s
general population since obesity, a major driver of
OSA,7 has greatly increased in the last decade.5 8
Furthermore, studies have shown that OSA is commonly
undiagnosed, suggesting an even higher prevalence of
adults who suffer from this sleep disorder.9–11
Surgical patients with OSA are at a higher risk of
developing postoperative respiratory complications
(PRCs), such as reintubation and requirement of non-
invasive ventilation.12–14 Upper airway collapse in the
perioperative setting results in hypoventilation and is an
important component of the mechanism of PRCs. In
studies previously reported by our laboratory, independ-
ent of OSA, reintubation and unplanned ICU admission
result in a 70-fold to 90-fold increase in in-hospital mor-
tality.15 16 However, despite an increased rate of PRCs,
SDB, as identiﬁed by diagnostic codes, was paradoxically
associated with lower mortality, hospital length of stay
and costs among certain surgical specialties.12 The
mechanisms of the opposed effects of OSA on respira-
tory complication rate and mortality are unclear. We
speculate that reintubation in patients with OSA is typic-
ally the consequence of upper airway dysfunction rather
than pulmonary pathology, and the former can be
treated more efﬁciently.
Mechanism of perioperative obstructive sleep apnoea
Quantiﬁcation of perioperative vulnerability to upper
airway collapse requires consideration of preoperative
and perioperative risk factors that affect the balance
between collapsing forces and dilating forces of the
upper airway. Perioperative anatomical and physiological
factors need to be taken into account.
Anatomical abnormalities increase collapsing forces
Anatomical risk factors in patients with OSA include a
reduction in the size of the retropalatal and retroglossal
airway.17 18 Perioperatively, anatomical vulnerability is
augmented, thereby increasing upper airway instability.
Figure 1A summarises perioperative risk factors that
can compromise upper airway anatomy. Mechanical
loads to the collapsible segments of the retropalatal and
retropharyngeal upper airway lead to physical compres-
sion of the airway. Clinically, such an extraluminal mech-
anical load can occur as a consequence of a
postoperative haematoma following cervical, otolaryngol-
ogy or thyroid surgery.19 20 In addition, peripharyngeal
oedema may occur in perioperative medicine as a conse-
quence of ﬂuid overload. Bradley and colleagues studied
the effects of antishock trouser inﬂation on upper
airway size, and reported narrowed pharynx and
enlarged neck circumference measured by acoustic
pharyngometry.21 Congestive heart failure increases the
AHI, which presumably, is the consequence of nocturnal
rostral ﬂuid shift.22 Airway patency may also be affected
by peripharyngeal inﬂammation and oedema in the
setting of intubation and extubation.
Impaired caudal traction on the trachea increases
collapsibility
Isono and colleagues have conducted extensive investiga-
tions of position-dependent effects on airway obstruc-
tion. In anaesthetised and paralysed patients with OSA,
the authors found that the lateral and sitting positions
improve the collapsibility of the passive pharyngeal
airway.23 24
Among patients with OSA, the supine position not
only promotes a more obstructive orientation of the pha-
ryngeal soft tissues, but also reduces caudal traction,
thereby increasing vulnerability to upper airway collapse.
During inspiration, caudal traction on the airway due
to lung expansion dilates and stabilises the upper airway,
a force that opposes the negative intraluminal pressure
and prevents collapse.25 The supine position during
surgery, immediate postoperative period, and transition
to sleep impairs tracheal traction on the airway and pro-
motes collapse,23 24 as illustrated in ﬁgure 1A. Tracheal
traction is also impaired by any event that reduces lung
volume, often secondary to diaphragmatic dysfunction.
Impaired function of the respiratory pump muscles (dia-
phragm and intercostal muscles) results in ineffective
expansion of the lung and occurs in the setting of
surgery and trauma.26 Pain-induced splinting and
pharmacological agents, such as opioids, decrease drive
to the respiratory pump muscles, thereby preventing full
lung inﬂation and reducing tracheal traction.27 Studies
in the intensive care unit have demonstrated how sys-
temic inﬂammation and mechanical ventilation dramat-
ically disrupts diaphragmatic function.28 29
Neuromuscular mechanisms of perioperative airway collapse
A balance between the upper airway dilator muscles
(genioglossus, tensor palatine) and the respiratory
pump muscles (diaphragm, intercostal muscles) exist to
maintain upper airway patency during wakefulness and
sleep, as illustrated in ﬁgure 1B. Respiratory pump
muscles generate inspiratory airﬂow associated with
negative intraluminal pressure, which is detected by
mechanoreceptors and transmitted to the upper airway
dilator muscles via the hypoglossal nerve. As a result, the
genioglossus contracts and stabilises the upper airway.
Respiration is also stimulated by hypoxia and hypercar-
bia, which are detected by chemoreceptors. In addition
to wakefulness, information transmitted by mechanore-
ceptors and chemoreceptors stimulate respiratory
arousal, which has been previously deﬁned as arousal
from sleep and other drug-induced or endogenous
impairments of consciousness.30 Cortical effects on
respiratory arousal are important, and any decrease in
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arousal can impair the voluntary effort to breathe spon-
taneously through a patent upper airway.31
A variety of pharmacological and non-pharmacological
perioperative factors affect respiratory arousal. While the
speciﬁc effects of perioperative pharmacological agents
depend on agent, dose and speciﬁc muscle group,
studies have shown that such agents largely dampen
stimulation to the nerves controlling respiratory muscles.
Anaesthetics and sedatives
Studies in humans and animals have demonstrated the
effects of anaesthetics on the upper airway by a variety
of mechanisms. Anaesthetics decrease muscle and
neural activity important for respiration as well as wake-
fulness through varying mechanisms.32 Propofol, an
agent commonly used for induction and maintenance
of anaesthesia, dose-dependently increases collapsibility
of the upper airway through depressed respiratory drive
to and direct inhibition of upper airway dilator muscle
activity in humans.33 In humans, anaesthetised with iso-
ﬂurane, reﬂexive activity or the responsiveness of upper
airway dilator muscles to negative pressure, was found to
be greatly reduced.34 The diminishing effects of anaes-
thetics on neuronal activity also differ between hypoglos-
sal and phrenic nerve.35 With a focus on neural
mechanisms for altered upper airway activity, Nishino
et al36 investigated the differential effects of anaesthetics
and found greater dampening of hypoglossal nerve
input relative to the phrenic nerve. This effect may
result in greater anaesthesia-induced impairment of
upper airway dilators compared to respiratory pump
muscles, increasing the upper airway’s propensity for col-
lapse. While this effect was observed across three classes
of drugs (volatile, barbiturate and benzodiazepine),
ketamine reduced neural input to the upper airway
dilator muscles and respiratory pump muscles equally.
Furthermore, ketamine’s effect on the upper airway
dilator muscles was less relative to GABAergic anaes-
thetics.36 Such ﬁndings are corroborated by mechanistic
studies in rats that demonstrate a dissociation between
loss of consciousness and upper airway dilator muscle
function under ketamine anaesthesia.37 Taken together,
studies suggest that patients with OSA, who have pre-
operative upper airway instability, may be at a heigh-
tened risk of upper airway collapse when under the
inﬂuence of anaesthetics. The unique effects associated
with ketamine, however, suggest that this drug may be a
safer choice for patients with OSA.
Opioids
The use of opioids for postoperative pain management
has been increasingly identiﬁed as a contributor to post-
operative exacerbation of SDB.38 39 Studies in human
and animal subjects have investigated the mechanism by
which patients with preoperative OSA may be vulnerable
to the effects of perioperative opioids. Patients with OSA
have increased sensitivity to pain40–42 as well as increased
sensitivity to the respiratory depressant effects of
Figure 1 Pathophysiology of perioperative obstructive sleep apnoea. (A) Pathological anatomy. This schematic of the
respiratory system demonstrates the anatomical forces (red arrows) increasing collapsibility of the upper airway (red curly lines).
Caudal tracheal traction stabilises the upper airway such that it is less vulnerable to collapse. CPAP treatment can evoke caudal
tracheal traction and increase end-expiratory lung volume. Collapsing physical forces are those that increase the mechanical load
on the upper airway (haematoma, oedema, fat) and those that reduce caudal tracheal traction (atelectasis, supine, flat position).
(B) Pathological physiology. The vulnerable perioperative upper airway physiology is illustrated as a scale, demonstrating the
fragile balance between activation of respiratory pump muscles and upper airway dilator muscles (green zone). When activated,
pump muscles generate negative inspiratory pressure and tip the balance to upper airway collapse (red zone). In normal
physiology, upper airway dilator muscles activate to counterbalance the negative inspiratory pressure and dilate the upper airway.
Underactivation of airway dilator muscles, such as the tongue muscle, will result in collapse (red zone). A variety of perioperative
events affect respiratory arousal, which can impair airway patency by overactivating pump or underactivating dilator muscles,
respectively. Patients with OSA are at higher vulnerability towards collapse, and the specific pathophysiological mechanism of
the increased perioperative vulnerability to collapse in OSA are emphasised in yellow colour and denoted with an asterisk. CPAP,
continuous positive airway pressure; OSA, obstructive sleep apnoea.
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opioids.43 Such ﬁndings are particularly relevant to the
patient with postoperative OSA given the effects of
opioids on upper airway patency. Animal studies have
shown that opioids increase upper airway resistance,
resulting in obstruction.44 Opioids directly inhibit hypo-
glossal motoneurons, which leads to suppressed genio-
glossus activity.45 Thus, the use of opioids during and
immediately after surgery is an important perioperative
factor to consider in patients with OSA when assessing
the risk of upper airway instability and the PRCs that
may arise as a consequence.
Neuromuscular blocking agents and reversal agents
Neuromuscular blockade agents act longer than the dur-
ation of surgery and postoperative residual curarisation
affects postoperative respiratory outcome.46 Upper
airway dilators are more vulnerable to minimal effects of
neuromuscular blocking agents compared to the respira-
tory pump muscles.47 48 This differential activation of
pump versus dilator muscles may set off an unwanted
chain of events such that the relatively more active
respiratory pump muscles generate excessive negative
intrathoracic pressure, resulting in negative pressure pul-
monary oedema.49 Even at levels producing minimal
blockade, as measured by train-of-four ratio 0.5–1,
neuromuscular blocking agents increased upper airway
collapsibility and impaired compensatory genioglossus
response to negative pharyngeal pressure challenges.50
Studies in surgical patients have demonstrated the dose-
dependent association between intermediate-acting
neuromuscular blocking agents and PRCs, an effect
shown to be unyielding despite neostigmine-based rever-
sal at end of surgery.16 51 52 On the basis of the patho-
physiology of the disease, patients with OSA should have
an increased vulnerability to the effects of neuromuscu-
lar blocking agents and reversal agents.47 50 53 However,
population-based studies aiming to quantify the effects
of residual neuromuscular blockade in patients with and
without risk of OSA are currently missing.
The impact of such pharmacological agents commonly
used in anaesthesia care on the risk of respiratory out-
comes in patients with OSA has yet to be determined.
Our study will address the unmet need of evaluating the
perioperative effect of neuromuscular blocking agents,
reversal agents, opioids, sedatives and anaesthetics in
patients at risk of OSA.
Non-pharmacological events
Non-pharmacological perioperative events, such as rapid
eye movement (REM) rebound, encephalopathy, delir-
ium, can disrupt respiratory arousal and result in upper
airway collapse.30 In the immediate postoperative
period, patients commonly experience poor quality, dis-
rupted and reduced sleep, resulting in a deﬁcit of REM
sleep.54 Sleep studies in surgical patients have identiﬁed
an REM rebound effect, in which REM sleep returns
acutely and suddenly.54 55 Increased amounts of REM
during sleep is associated with impaired respiratory
arousal and more frequent episodes of nocturnal hypox-
aemia.56 Patients with OSA also have diminished or lost
airway reﬂex during non-REM sleep, so patients with
OSA may be at an even greater propensity for upper
airway collapse and hypoxaemia with phenomenon of
REM rebound. While patients with OSA have been
shown to compensate for diminished airway sizes with
higher basal genioglossus muscle activity,57 this neuro-
muscular compensation has been found to be present
only during wakefulness, and thus, futile in the setting
of REM-predominant sleep. Recent prospective studies
have demonstrated a signiﬁcant reduction in REM sleep
in patients with and patients without OSA during the
early postoperative period.58 Postoperatively, time spent
in REM sleep did not consistently predict postoperative
OSA severity,38 which may be the consequence of REM
suppression secondary to postoperative pain, as well as
administration of opioids and sedatives. Of note, studies
have also identiﬁed other important contributors to
SDB. Events that impair a patient’s level of consciousness
also disrupt respiratory arousal and result in upper
airway instability. Such events include delirium, stroke,
septic encephalopathy, systemic inﬂammation and meta-
bolic disturbances, such as hypoglycaemia and
hypothyroidism.30
Study rationale
In order to evaluate the perioperative risk of patients
presenting with OSA, it is important to take into
account the ‘true’ prevalence of the disease in the peri-
operative cohort. An important limitation of the existing
literature relates to the focus on patients who carry the
clinical diagnosis of OSA. As a consequence of analysing
only those patients with an International Classiﬁcation
of Diseases 9 (ICD-9) diagnostic code for SDB, a large
subpopulation with undiagnosed OSA remain
undetected.
The gold standard for the diagnosis of OSA is poly-
somnography. According to current clinical guidelines
for OSA evaluation, patients are prompted to undergo
this sleep study if determined to be high risk by their
physician.3 As a routine evaluation for OSA, polysomno-
graphy is impractical because of its limited availability,
discomfort to the patient and high cost.59 60 The use of
screening tools for OSA helps identify patients at risk of
OSA. Widely used scores include the Perioperative Sleep
Apnea Prediction Score,61 the STOP-Bang62 and Berlin
Questionnaires,63 and the Epworth Sleepiness Scale.64
Such scores rely on a clinical exam to determine neck
circumference and/or patient questionnaire of daytime
OSA symptoms. Not all patients are able to have their
necks measured, and many patients are asymptomatic or
unaware of their symptoms, limiting the ability of the
existing scores to assess true prevalence of OSA.
Anaesthesiologists have also used scores, such as the
Mallampati Score and the American Society of
Anesthesiologists (ASA) Checklist, to assess difﬁculty of
intubation as related to a narrow upper airway,65 but
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there is inconsistency in reported sensitivity and speciﬁ-
city of the Mallampati score as a predictor of OSA.64
Furthermore, the currently available scores require data
not routinely available from clinical databases, such as
history of snoring and witnessed apnoea. This proposal
is based on the consideration that other data available in
the patient’s electronic medical record may be sufﬁcient
to predict OSA and its associated increased risk of PRCs.
Application of our prediction score on large periopera-
tive data sets will permit research endeavours, such as
the evaluation of the effect of OSA on patient outcomes
and the justiﬁcation of healthcare resource usage.
Furthermore, understanding how pharmacological
agents commonly used in perioperative care impact post-
operative outcomes among patients with high risk of
OSA will improve our ability to provide better care for
this vulnerable surgical population. Traditionally, anaes-
thesia providers have determined dosing of various
drugs based on standard parameters of age, gender,
height and weight. However, such practices may not suf-
ﬁciently guide providers in optimal drug administration,
especially in a subpopulation more vulnerable to the
effects of those drugs as already demonstrated in the lit-
erature. More speciﬁcally, we would like to better under-
stand the interaction between the disease OSA and
opioids, neuromuscular blocking agents, neostigmine,
sedatives and anaesthetics to optimally predict post-
operative respiratory outcomes. Using our prediction
score for OSA in a large perioperative database, we will
evaluate how the use of pharmacological agents modiﬁes
the risk of PRCs in patients with OSA.
Objectives
The primary objectives are to:
1. Develop and validate a novel prediction score of OSA
to identify patients at high risk of OSA based on
markers of the disease easily available from clinical
databases.
2. Evaluate the effect of being at high risk of OSA, as
deﬁned by the prediction score, on the primary
outcome of PRCs among patients undergoing
surgery at Massachusetts General Hospital.
3. Evaluate if use of neuromuscular blockade,
neostigmine-based reversal of neuromuscular block-
ade, opioids, sedatives and anaesthetics modify the
risk of OSA on PRCs.
The secondary objective is to:
Investigate whether the association between OSA risk
and PRCs is modiﬁed by age, gender, body mass index
(BMI) and major comorbidities.
Hypotheses for the primary outcome
On the basis of previous data,12 we hypothesise that
patients with a high risk of OSA, as identiﬁed by our
new prediction instrument, are more vulnerable to acute
postoperative upper airway failure that leads to reintuba-
tion. We further hypothesise that such patients will
experience less favourable outcomes depicted as
intensive care unit admission rate, hospital length of stay
and hospital costs.
As a departure from the current literature on the peri-
operative effects of OSA, we believe that perioperative
variables, which increase the vulnerability to airway col-
lapse, will give us clinically meaningful information in
order to predict which patient with OSA will develop
PRCs.
METHODS AND ANALYSIS
Study overview
The proposed study is a retrospective cohort analysis
using hospital-based electronic patient data and peri-
operative data on medications administered and patient
vital signs. We will use data from major clinical databases
at Massachusetts General Hospital, a tertiary care facility
and teaching hospital of Harvard Medical School in
Boston, Massachusetts. In addition, polysomnography
data will be extracted from clinical databases at several
hospitals afﬁliated with Partners Healthcare.
As previously used for epidemiological studies by our
group, data from two clinical databases will be retrieved
and combined to provide de-identiﬁed preoperative,
intraoperative and postoperative information: the
Research Patient Data Registry and the Anesthesia
Information Management System.15 16 51 66 The
Research Patient Data Registry contains demographic
and billing data regarding patient comorbidities and
postoperative outcome and survival. The Anesthesia
Information Management System contains physiological
data from patient monitors as well as information on
medical history and documentation of important
surgery and anaesthesia-related events, including adverse
events, perioperative procedures, and drug and ﬂuid
therapy. In addition, we will extract data related to hos-
pital length of stay, discharge, and cost of care from our
institution's administrative database, EPSi. Patient data
from these databases are linked through unique patient
identiﬁers, and the variables described in this protocol
will be abstracted to form one database. The present
database spans January 2007 to August 2014, and
includes 140 000 surgical cases. On the basis of previous
work, we will conservatively anticipate that 25% of the
cases will not satisfy inclusion criteria due to patient’s
age, emergency status and missing data.15 51 Thus, we
estimate 100 000 patient cases will meet our inclusion
criteria.
Subject selection
For the three primary objectives, we will include all adult
surgical patients who underwent general anaesthesia
and received endotracheal intubation or airway manage-
ment by supraglottic airway device at our institution, for
whom inpatient admission was planned, between
January 2007 and August 2014. Because reintubation is a
component of our composite outcome of PRCs, we will
only include those patients who have had removal of all
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airway management devices within the operating room
after the procedure. Surgical procedures followed by
reintubation for an additional scheduled surgical pro-
cedure in the operating room after initial extubation or
removal of airway device will be excluded from the
study, as we presume that such cases did not require
reintubation in the setting of adverse postoperative
respiratory status. Patients who underwent surgery in the
4 weeks prior to the study case will be excluded. Finally,
all patients with an intraoperative death will be excluded
from the study since OSA is not a biological mechanism
of intraoperative death when a patient’s airway is secure
by an airway device. Patients will be identiﬁed using
anaesthesia data obtained from Research Patient Data
Registry and Anesthesia Information Management
System.
The study methods are outlined in three sections to
address the three primary objectives.
Objective 1: Development of prediction model for OSA
Prediction model reference standard
The reference standard for the prediction model will be
deﬁned as patients with an ICD-9 OSA diagnosis follow-
ing the appearance of a polysomnography procedural
(CPT, Current Procedural Terminology) code in our
medical databases (ﬁgure 2). From this speciﬁc
sequence of events, we infer that these patients had
their clinically suspected OSA diagnosis conﬁrmed by
polysomnography.
Validation of reference standard for the diagnosis of OSA
Prior to the development of the prediction model, we
will conduct a medical chart review of 100 randomly
selected patients in order to determine whether or not
such patients actually have evidence of OSA in the time
between their polysomnography and surgery. This
cohort of patients will consist of 50 cases of OSA, accord-
ing to our criteria of ICD 9 diagnostic code and poly-
somnography CPT code, and 50 cases without OSA. A
blinded chart review will be performed on this mixed
group of 100 cases. Conﬁrmatory evidence of OSA
would include a reported AHI ≥5 as documented in a
patient’s medical chart,2 or treatment with continuous
positive airway pressure. The predictive model will be
performed if the ICD-9 and CPT code combination has
an acceptable positive predictive value (≥0.8).
Predictor variables
A number of variables have been found to be associated
with an increased prevalence of OSA and are currently
used for different screening tools for OSA in surgical
patients.62 65 67 From the Anesthesia Information
Management System and Research Patient Data Registry
databases, we will obtain and include the following data
in our prediction score: age, BMI, gender and the ASA
physical status classiﬁcation (ﬁgure 2). We will incorpor-
ate medical comorbidities using ICD-9 diagnostic codes,
some of which are deﬁned by the Deyo-Charlson
Comorbidity Index (table 1).68 All covariates included in
the prediction model must be present within 1 year of
surgery date. In addition, as a departure from current
literature on developing OSA screening scores, we will
consider oxygen desaturation immediately after extuba-
tion as a predictor. This strategy will most likely increase
the predictive value of our score—patients with OSA are
very vulnerable to desaturation after surgery, and we
have the unique opportunity to use this characteristic of
OSA desaturation after anaesthesia that has not yet been
used in existing prediction scores. Postextubation
oxygen desaturation will be deﬁned as an oxyhaemoglo-
bin reading <90%, and <80% for at least 1 min, as mea-
sured by pulse oximetry during the ﬁrst 10 min after
extubation in the operating room.
Development of prediction model
We will use an unconditional logistic regression model
with an automated forward selection procedure to select
for predictors of our a priori deﬁned reference stand-
ard. To determine the goodness-of-ﬁt of the ﬁnal predic-
tion model, we will use the Hosmer-Lemeshow test,
which indicates that there is no signiﬁcant difference
between observed and expected OSA status if p value
≥0.05. A point value will be assigned to each predictor
variable proportional to the estimates from the logistic
regression. The predictive value of the score for OSA
will be assessed using c-statistics, which is equivalent to
the area under the ROC curve.69 We will aim to achieve
a minimum c-statistic of 0.8. In addition, we will evaluate
if the addition of a variable that can be obtained by
anaesthesiologists at the end of the surgical case, for
example, postextubation desaturation, improves the pre-
dictive ability of the score. For this purpose, we will use
risk reclassiﬁcation analysis to compare the clinical
impact of these two models.70 71 The net reclassiﬁcation
improvement will be generated by balancing the propor-
tion of subjects whose risk was more accurately classiﬁed
using the expanded prediction model with postextuba-
tion desaturation compared with the prediction model
without postextubation desaturation against the propor-
tion of participants whose risk was less accurately
classiﬁed.70
We will calculate positive and negative likelihood ratios
for each stratum of the score. We will use bootstrap tech-
niques to determine the robustness of included vari-
ables, which are close to the p value cut-off of 0.05. We
will then use classiﬁcation tables to determine the best
cut-off value for the prediction score to classify patients
at high risk for OSA. We will also use cross-validation to
evaluate any potential overﬁtting of our prediction
model.
Objective 2: Effect of high OSA risk on postoperative
respiratory complications
Exposure variables
Our primary exposure variable of interest is OSA risk, as
deﬁned by our prediction model developed in aim
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1. We will identify patients in our population as having a
high, moderate and low risk for OSA using our predic-
tion model, and produce three cohorts of patients,
which we will follow for the occurrence of outcome
events.
Outcome variables
The primary outcome of this part of the study is a com-
posite outcome deﬁned as the incidence of
reintubation, pulmonary oedema, pneumonia and
respiratory failure within the ﬁrst three postoperative
days. Secondary outcomes include the aforementioned
individual outcomes as well as hospital length of stay,
duration of postanaesthesia care unit treatment and
in-hospital mortality. Hospital length of stay will be
deﬁned as the postoperative length of hospital stay fol-
lowing surgery. The primary outcome has been previ-
ously used and validated by chart review.51 66 The
outcomes events for the primary analysis will be identi-
ﬁed by ICD-9 diagnostic and CPT procedural codes
obtained from the Research Patient Data Registry data-
base (table 1).
Figure 2 Aim 1: Development of prediction model for high, moderate, and low risk of OSA (CPT, Current Procedural
Terminology; ICD, International Classification of Diseases; OSA, obstructive sleep apnoea).
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Table 1 Diagnostic (ICD-9) and procedural (CPT) codes used to generate predictor and outcome variables
Variable Diagnostic or procedure name
Code
type Code
Reference standard outcome for prediction model of aim 1
Obstructive sleep
apnoea
Obstructive sleep apnoea (adult or paediatric) ICD-9 327.23
Unspecified sleep apnoea ICD-9 780.57
Polysomnography Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or
heart rate, oxygen saturation, attended by a technologist
CPT 95807
Any age, sleep staging with 1–3 additional parameters of sleep, attended by a
technologist
CPT 95808
Age 6 years or older, sleep staging with 4 or more additional parameters of
sleep, attended by a technologist
CPT 95810
Age 6 years or older, sleep staging with 4 or more additional parameters of
sleep, with continuous positive airway pressure therapy or bi-level ventilation,
attended by a technologist
CPT 95811
Medical comorbidities
Arterial hypertension Malignant essential hypertension ICD-9 401.0
Benign essential hypertension ICD-9 401.1
Unspecified essential hypertension ICD-9 401.9
Other malignant secondary hypertension ICD-9 405.09
Other benign secondary hypertension ICD-9 405.19
Other unspecified secondary hypertension ICD-9 405.99
Pulmonary
hypertension
Pulmonary hypertension ICD-9 416.0
Coronary artery
disease
Coronary atherosclerosis of unspecified type of vessel native or graft ICD-9 414.00
Coronary atherosclerosis of native coronary artery ICD-9 414.01
Coronary atherosclerosis of autologous vein bypass graft ICD-9 414.02
Coronary atherosclerosis of non-autologous biological bypass graft ICD-9 414.03
Coronary atherosclerosis of artery bypass graft ICD-9 414.04
Coronary atherosclerosis of unspecified bypass graft ICD-9 414.05
Coronary atherosclerosis of native coronary artery of transplanted heart ICD-9 414.06
Coronary atherosclerosis of bypass graft (artery) (vein) of transplanted heart ICD-9 414.07
Aneurysm of heart (wall) ICD-9 414.10
Aneurysm of coronary vessels ICD-9 414.11
Dissection of coronary artery ICD-9 414.12
Other aneurysm of heart ICD-9 414.19
Chronic total occlusion of coronary artery ICD-9 414.20
Coronary atherosclerosis due to lipid rich plaque ICD-9 414.30
Coronary atherosclerosis due to calcified coronary lesion ICD-9 414.40
Other specified forms of chronic ischaemic heart disease ICD-9 414.80
Chronic ischaemic heart disease unspecified ICD-9 414.90
Dyslipidemia Pure hypercholesterolaemia ICD-9 272.0
Pure hyperglyceridaemia ICD-9 272.1
Mixed hyperlipidaemia ICD-9 272.2
Hyperchylomicronemia ICD-9 272.3
Other and unspecified hyperlipidaemia ICD-9 272.4
Other disorders of lipoid metabolism ICD-9 272.8
The following medical comorbidities are derived from ICD-9 codes, as defined by the Deyo Charlson Comorbidity Index:68
Myocardial Infarction, Congestive Heart Failure, Peripheral Vascular Disease, Cerebrovascular Accident, Dementia, Chronic
Pulmonary Disease, Mild Liver Disease, Moderate to Severe Liver Disease, Diabetes with Chronic Complications, Diabetes
without Chronic Complications, Hemiplegia or Paraplegia, Peptic Ulcer Disease
Primary Outcome for Aim 2 and Aim 3
Pneumonia Pneumococcal pneumonia (Streptococcus pneumonia) ICD-9 481
Pneumonia due to Klebsiella pneumoniae ICD-9 482.0
Pneumonia due to Pseudomonas ICD-9 482.1
Pneumonia due to Streptococcus, unspecified ICD-9 482.30
Pneumonia due to Staphylococcus, unspecified ICD-9 482.40
Pneumonia due to Staphylococcus aureus ICD-9 482.41
Methicillin resistant pneumonia due to Staphylococcus aureus ICD-9 482.42
Pneumonia due to Escherichia coli ICD-9 482.82
Continued
8 Shin CH, et al. BMJ Open 2016;6:e008436. doi:10.1136/bmjopen-2015-008436
Open Access
Outcome model
We will perform multivariable logistic regression analyses
to evaluate the effect of estimated OSA risk on our
respiratory outcomes. Results will be presented as an
age-adjusted and multivariable-adjusted OR with 95%
CIs. We will consider a two-tailed p value of <0.05 as stat-
istically signiﬁcant.
To control for confounding effects, we will consider a
priori the following risk factors: age, gender, BMI, ASA
physical status classiﬁcation, comorbidities, surgical spe-
cialty, duration of the surgical procedure, admission type
and emergency status.16 We will additionally control for
dose of anaesthesia (median dose of anaesthetic agents
corrected for age),72 opioids (calculated as total
morphine equivalent dose),73 vasopressors, sedatives,
neuromuscular blocking agents and neostigmine use
(ﬁgure 3).
The effect of surgery type will be analysed in greater
detail by grouping similar types of surgery (eg, cardiovas-
cular, laparoscopic) to determine if surgery type is an
effect modiﬁer and not a confounder. If this is found to
be the case, surgical specialty will no longer be included
as a covariate, and the previously described model will
be stratiﬁed by surgery type.
Sample size and power calculations
On the basis of previous work with data from surgical
patients in our institution, we expect approximately
100 000 patients undergoing surgery to meet our inclu-
sion criteria during the observational period. Studies on
prevalence of OSA in the general surgical population
provide a range of estimates: one study found 17% of
surgical patients as having severe OSA (AHI>30).11
Other studies relying on screening scores found any-
where from 4.8%74 to 41.6%75 of surgical patients at
high risk of OSA. Thus, we conservatively estimate 3%
(n=3000) patients in our surgical population to have a
high likelihood of OSA. Basing on our prediction score,
we will classify patients as high, moderate and low OSA
risk.
Previous work by our laboratory51 found an overall
incidence of 3.7% for our primary outcome of PRCs.
Data on differences in postoperative outcomes between
OSA and non-OSA groups provide us with estimates for
our predicted intergroup differences. Liao et al13 found
an intergroup (OSA vs non-OSA) difference of 11% for
their composite outcome of total respiratory complica-
tions. Mokhlesi et al12 investigated the incidence of
emergent intubation following elective surgery among
patients with and without SDB. Emergent intubation
occurred at a rate of 3.5–11.4% among patients with
SDB versus 0.3–7% among patients without SDB across
four categories of elective surgery.12 The intergroup dif-
ference observed was approximately 3%.12 Basing on
this data, we will conservatively estimate an intergroup
difference of 10% for our composite outcome, with
smaller differences observed for outcomes with lower
Table 1 Continued
Variable Diagnostic or procedure name
Code
type Code
Pneumonia due to other Gram-negative bacteria ICD-9 482.83
Pneumonia due to other specified bacteria ICD-9 482.89
Bacterial pneumonia, unspecified ICD-9 482.9
Pneumonia, organism unspecified ICD-9 486
Pneumonia due to other specified organism ICD-9 483.8
Pneumonia in aspergillosis ICD-9 484.6
Bronchopneumonia, organism unspecified ICD-9 485
Pneumonitis due to inhalation of food or vomitus ICD-9 507.0
Pulmonary oedema Pulmonary congestion and hypostasis ICD-9 514
Acute oedema of lung, unspecified ICD-9 518.4
Congestive heart failure ICD-9 428.0
Fluid overload ICD-9 276.6
Other fluid overload ICD-9 276.69
Reintubation Intubation, endotracheal, emergency procedure CPT 31500
Ventilation assist and management, initiation of pressure or volume preset
ventilators for assisted or controlled breathing; hospital inpatient/observation,
initial day
CPT 94002
Respiratory failure Pulmonary insufficiency following trauma and surgery ICD-9 518.5
Acute respiratory failure following trauma and surgery ICD-9 518.51
Other pulmonary insufficiency, not elsewhere classified, following trauma and
surgery
ICD-9 518.52
Respiratory failure ICD-9 518.81
Other pulmonary insufficiency, not elsewhere classified ICD-9 518.82
Acute and chronic respiratory failure ICD-9 518.84
CPT, Current Procedural Terminology; ICD, International Classification of Diseases.
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frequencies. Power is calculated based on comparing
proportions of outcome rates between expected patients
with OSA and the reference population without OSA.
Our ﬁxed sample size of 100 000 will provide us with a
power >90% to identify a 10% intergroup difference
with an α error of 0.05.
Objective 3: Risk modification by pharmacological agents
Exposure variable and rationale
We will obtain data on the intraoperative use of
intermediate-acting neuromuscular blocking agents,
neostigmine-based reversal of neuromuscular blockade,
opioids, anaesthetics and sedatives as additional
Figure 3 Aim 2: Effect of high OSA risk on postoperative respiratory complications (ASA, American Society of
Anesthesiologists; BMI, body mass index; OSA, obstructive sleep apnoea; PRC, postoperative respiratory complication).
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independent variables in the analysis to test whether or
not such pharmacological agents modify the effect of
OSA on the risk for PRCs (ﬁgure 4). We have previously
studied the use of intermediate-acting neuromuscular
blocking agents and found that their use was associated
with an increased risk of respiratory complications.16 In
addition, we have observed that the use of the reversal
agent neostigmine does not decrease but increase the
risk of PRCs.16 52 However, recent work demonstrates
that such effects could be mitigated by neostigmine only
at low doses and with simultaneous careful monitoring
of neuromuscular transmission (train-of-four).51
Patients with OSA should be at high risk of respiratory
complications induced by pharmacological agents
because such agents can affect upper airway
patency.35 44 48 76 We thus expand our investigation to
include the risk modiﬁcation effect of pharmacological
agents (neuromuscular blocking agents, neostigmine,
opioids, anaesthetics and sedatives) on PRCs in a subpo-
pulation of surgical patients who may be at an inherent
higher vulnerability towards upper airway collapse and
subsequent poor respiratory outcomes. Similar to previ-
ous work, we will extract information on administration
of pharmacological agents from the Anesthesia
Information Management System database.51
Outcome variables
The primary outcome is the composite variable of PRCs,
consisting of: reintubation, pulmonary oedema, pneumo-
nia and respiratory failure. Secondary outcomes include
hospital length of stay, duration of postanaesthesia care
unit treatment, inhospital mortality, as well as the afore-
mentioned outcomes. These outcomes are deﬁned by
ICD-9 and CPT codes located in the Research Patient
Data Registry database, and have been previously vali-
dated by chart review by our laboratory (table 1).51
Stratified analysis to assess for effect modification by
pharmacological agents
To evaluate potential effect modiﬁcation by neuromus-
cular blockade, neostigmine, opioid, anaesthetic and
sedative use, we will run stratiﬁed analyses of the associ-
ation between OSA and the outcome events based on
intraoperative use of pharmacological agents. We will
use the likelihood ratio test to contrast our main model
to a model including interaction terms between OSA
and the following variables: neuromuscular blocking
agent dose, opioid dose and median effective dose of
anaesthetics. To control for confounding effects, we will
consider a priori the following risk factors: age, gender,
BMI, ASA physical status classiﬁcation, comorbidities,
surgical specialty, duration of the surgical procedure and
emergency status.16 The stratiﬁed analyses for neuromus-
cular blockade, opioid, anaesthetic and sedative use will
be performed independently using stratiﬁed versions of
the previously described model. The potential for risk
modiﬁcation of neostigmine will be performed in the
subset of patients receiving neuromuscular blockade.
Study cohorts
On the basis of previous work with data from surgical
patients in our institution, approximately 100 000
patients will meet inclusion criteria. On the basis of data
estimating OSA prevalence in the general surgical popu-
lation, we conservatively expect to ﬁnd approximately
3000 patients with high likelihood of OSA in our surgi-
cal population. Using our prediction model from aim 1,
we will determine the risk of OSA and assign patients
found to be at high, moderate and low risk of OSA.
Ethics and dissemination
This study uses internal hospital-based data routinely col-
lected for medical documentation purposes. As it is a sys-
tematic review of the data, there is little ethical risk. Patient
privacy and protection of health information will be main-
tained. The results of this study will be shared in the form
of presentations at national and international meetings.
The complete study and conclusions regarding the
primary objectives will be presented in manuscript form.
Limitations and strengths
This article presents the protocol and data analysis plan
for the development of a novel prediction score for OSA
and application of the score to more accurately charac-
terise the risk imparted by OSA condition on PRCs.
Our approach relies on the investigation of patient
data on ﬁle. Thus, our ﬁndings depend on the quality of
the database which is susceptible to measurement biases.
There is potential for variability in the input of billing
diagnoses and codes. This database has been used in
previous studies15 16 and demonstrated to have high spe-
ciﬁcity following veriﬁcation of diagnostic codes positive
for study’s composite outcome variable. Furthermore,
we will validate the use of diagnostic and procedural
codes in the development of our prediction model by
medical record review. Nevertheless, it is possible that
information is left out of some patients’ charts and, con-
sequently, our database of our composite outcomes and
independent variables. A second limitation involves our
inability to capture those patients admitted to an outside
hospital with PRCs after discharge from our institution.
A third limitation rises from the multifactorial and
dynamic nature of OSA: patients diagnosed with OSA,
even by polysomnography, may not necessarily have evi-
dence of OSA on the day of surgery. An example would
be a patient who loses signiﬁcant weight just prior to
surgery. Diagnosis of OSA by polysomnography prior to
weight loss may no longer be valid following weight
loss.77 Thus, we are limited in our development of a pre-
diction model since we initially rely on polysomnography
procedure codes and ICD-9 diagnoses as our standard.
We hope to minimise this limitation by developing a pre-
diction model that relies on variables that are highly
likely to predict OSA even in the absence of polysomno-
graphic evidence or clinical diagnosis.
In spite of these limitations, our study derives its
strengths from a number of key elements. Our database
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is large and includes a variety of surgical procedure
types and methods of anaesthesia, thus increasing the
generalisability of the study results and applicability of
our prediction score models. In addition, we have a
multidisciplinary team, which includes population scien-
tists, data analysts and clinicians. Such a team provides
Figure 4 Aim 3: Risk modification by pharmacological agents (ASA, American Society of Anesthesiologists; BMI, body mass
index; OSA, obstructive sleep apnoea; REM, rapid eye movement).
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the experience and skill level needed for efﬁcient, accur-
ate and precise design and analysis of the current study.
Our team has also previously developed prediction
scores for PRCs.15
CONCLUSIONS
The present study examines patients who we presume to
have a high risk of perioperative respiratory failure:
patients with OSA. The prediction score we develop to
assess OSA risk will be a useful and practical tool for
further OSA research and care. We believe the results of
this study will provide new insight on whether or not
high risk for OSA increases a patient’s risk of developing
PRCs, independent of other perioperative risk factors.
Moreover, the results of this study might be important to
evaluate the effects of interventions, such as reversing
neuromuscular blockade, on respiratory outcome of
OSA in the perioperative setting.
By developing a prediction score for OSA risk, we
hope to identify those patients who would beneﬁt from
speciﬁc preoperative interventions to minimise post-
operative morbidity and mortality.
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